Medication-Related Osteonecrosis of the Jaw Associated with Pazopanib Monotherapy

2022 • Volume 16 • Issue 1

Raquel D’Aquino Garcia Caminha; Guilherme Simpione; Vanessa Soares Lara & Paulo Sérgio da Silva Santos



Pazopanib, an antiangiogenic agent, has shown promising results in controlling tumor growth and metastasis in patients with renal cell carcinoma. The use of pazopanib in the management of malignancies has increased over recent years, with more patients at risk of developing medication-related osteonecrosis of the jaw (MRONJ). This paper presents the first case report of MRONJ associated with pazopanib monotherapy. A 59-year-old man was referred to the dental clinic with complaints of dysphagia and dysgeusia. The patient was prescribed pazopanib (400 mg) daily following surgical treatment and chemotherapy for metastatic renal cell carcinoma. He had undergone extraction of the maxillary left second premolar nine weeks previously. Intraoral examination revealed exposed necrotic bone, which was treated effectively with leukocyte and platelet-rich fibrin (LPRF). The patient was followed up for 150 days after dental treatment with no signs of relapse.

KEY WORDS: osteonecrosis, jaws, pazopanib, oncology.


How to cite this article

CAMINHA, R. D. G.; SIMPIONE, G.; LARA, V. S.; SANTOS, P. S. S. Medication-related osteonecrosis of the jaw associated with pazopanib monotherapy. Int. J. Odontostomat., 16(1):23-26, 2022.


PDF of the article.